Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3101
Bel Fuse Inc Class A
BELFA
$3.4B
| $252K | ﹤0.01% |
25,100
+500
| +2% | +$4.47K |
|
|
BIOL
3102
DELISTED
Biolase, Inc.
BIOL
| $252K | ﹤0.01% |
218
+193
| +772% | +$220K |
|
3103
BGSF Inc
BGSF
$59.2M
| $251K | ﹤0.01% |
22,200
-93,500
| -81% | -$957K |
|
|
WSO.B
3104
Watsco Inc Class B
WSO.B
| $250K | ﹤0.01% |
1,400
+100
| +8% | +$16.8K |
|
3105
Kodak
KODK
$978M
| $248K | ﹤0.01% |
111,331
-118,169
| -51% | -$275K |
|
|
TYME
3106
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $248K | ﹤0.01% |
+186,531
| New | +$254K |
|
|
FRTA
3107
DELISTED
Forterra, Inc
FRTA
| $246K | ﹤0.01% |
22,000
-202,073
| -90% | -$1.67M |
|
3108
Microbot Medical
MBOT
$113M
| $245K | ﹤0.01% |
35,400
-79,513
| -69% | -$538K |
|
|
GENE
3109
DELISTED
Genetic Technologies Ltd.
GENE
| $242K | ﹤0.01% |
21,233
-11,388
| -35% | -$116K |
|
3110
Replimune Group
REPL
$1.42B
| $241K | ﹤0.01% |
9,700
-8,000
| -45% | -$141K |
|
|
MRUS
3111
DELISTED
Merus
MRUS
| $240K | ﹤0.01% |
14,900
| – | – |
|
|
PLXP
3112
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| $240K | ﹤0.01% |
73,983
-417
| -0.6% | -$1.26K |
|
3113
DNA X Inc
SONM
$5.05M
| $238K | ﹤0.01% |
165
+145
| +725% | +$232K |
|
|
DLA
3114
DELISTED
Delta Apparel Inc.
DLA
| $238K | ﹤0.01% |
19,600
-5,600
| -22% | -$64K |
|
|
FFBW
3115
DELISTED
FFBW, Inc. Common Stock
FFBW
| $238K | ﹤0.01% |
27,626
-6,347
| -19% | -$55.9K |
|
|
JP
3116
DELISTED
Jupai Holdings Limited American depositary shares, each representing six ordinary shares
JP
| $237K | ﹤0.01% |
156,678
+70,578
| +82% | +$87.4K |
|
3117
Keros Therapeutics
KROS
$211M
| $236K | ﹤0.01% |
+6,300
| New | +$194K |
|
|
KREF
3118
KKR Real Estate Finance Trust
KREF
$502M
| $235K | ﹤0.01% |
14,200
-116,900
| -89% | -$1.85M |
|
|
EPIX
3119
DELISTED
ESSA Pharma
EPIX
| $234K | ﹤0.01% |
+37,777
| New | +$179K |
|
3120
Integrated Media Technology
IMTE
$1.84M
| $231K | ﹤0.01% |
+6,249
| New | +$231K |
|
3121
Yatra Online
YTRA
$55.3M
| $231K | ﹤0.01% |
340,402
+129,502
| +61% | +$139K |
|
|
MSON
3122
DELISTED
Misonix Inc
MSON
| $231K | ﹤0.01% |
17,007
-42,448
| -71% | -$519K |
|
3123
HNI Corp
HNI
$3.56B
| $229K | ﹤0.01% |
7,500
-119,000
| -94% | -$3.03M |
|
3124
WisdomTree Europe SmallCap Dividend Fund
DFE
$169M
| $228K | ﹤0.01% |
4,600
-12,500
| -73% | -$574K |
|
3125
Outfront Media
OUT
$5.24B
| $227K | ﹤0.01% |
16,256
-2,807,358
| -99% | -$39.4M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.